|Bid||5.97 x 800|
|Ask||5.98 x 800|
|Day's Range||5.90 - 6.05|
|52 Week Range||3.55 - 8.89|
|Beta (3Y Monthly)||0.25|
|PE Ratio (TTM)||3.35|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On a per-share basis, the Clearwater, Florida-based company said it had a loss of 14 cents. The medical device maker posted revenue of $5.8 million in the period. Apyx expects full-year revenue in the ...
Shares of Apyx Medical Corp. plummeted 37% toward 9-month low in morning trade Tuesday, after the company formerly known as Bovie Medical Corp. said it was withdrawing its application for regulatory clearance of its J-Plasma/Renuvion for use in dermal resurfacing procedures. The stock, which was pacing all decliners on the Nasdaq exchange, and was on track for the biggest one-day drop since January 2000. The company said late Monday that the withdrawal of its application for premarket notification 510(k) was voluntary, and followed an investigational device exemption study that failed to meet the primary efficacy endpoint. The company said it cannot provide a timeline for re-submission, but said it plans to do so after further discussions with the Food and Drug Administration. The stock has now low 33% year to date, but was still up 49% over the past 12 months. In comparison, the S&P 500 has gained 11% over the past year.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 1) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...
In the latest trading session, Apyx Medical (APYX) closed at $6.31, marking a -0.63% move from the previous day.
A look at the shareholders of Apyx Medical Corporation (NASDAQ:APYX) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect toRead More...
The Clearwater, Florida-based company said it had a loss of 12 cents per share. Losses, adjusted to account for discontinued operations, were 10 cents per share. The medical device maker posted revenue ...
Apyx (APYX) delivered earnings and revenue surprises of 0.00% and -1.07%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 12) Elanco Animal Health Inc (NYSE: ELAN ) CareDx Inc ...
Conatus (CNAT) makes an improvement with narrower-than-expected loss in the fourth quarter of 2018. Also, revenues beat mark.